Human Antibody Therapeutics For Viral Disease

od Scott K. Dessain - Sprzedaje Dodax EU
Stan: Nowy
746,79 zł
Zawiera podatek VAT, darmowa dostawa
Scott K. Dessain Human Antibody Therapeutics For Viral Disease
Scott K. Dessain - Human Antibody Therapeutics For Viral Disease

Podoba Ci się ten produkt? Przekaż dalej!

746,79 zł zawiera VAT
Dostępnych sztuk: 1 Dostępnych tylko 2 sztuk
Dostawa: między 2020-12-08 a 2020-12-10
Sprzedaż i wysyłka: Dodax EU


Although the utility of human antibodies as medical therapeutics for cancer and immune diseases has been well-established, it is only beginning to be realized for the treatment of viral infectious diseases. Polyclonal immunoglobulins have long been used for some viral diseases, but they have limited potency and disease scope. Only a single humanized monoclonal antibody (pavilizumab) has been approved as a viral countermeasure. The articles in this volume have been selected to demonstrate the progress in the development of human antibody therapeutics for viral disease. Keck et al. review the nature of the immune response to the Hepatitis C virus (HCV) and the details of viral neutralization by antibodies, providing a conceptual model for the clinical use of HCV-specific antibodies. Huber et al. summarize the initial clinical experiences with antibody therapeutics for Human Immunodeficiency Virus that can be targeted to either the HIV virion or to host cell proteins. A discussion of the breadth immune strategies that is required to control human rabies is provided by Nagarajan et al., with a particular focus on India and other countries in which rabies is endemic. The development of pavilizumab for RSV prophylaxis is reviewed in Wu et al., in addition to results of antibody optimization studies that provide surprising insights and have broad general implications for anti-viral antibody engineering. Melhop and Diamond explicate the biology of West Nile Virus as a general model for flaviviruses, while using their cloned antibodies as a springboard to consider the mechanisms of WNV neutralization. The volume concludes with a description of methods to clone human antibodies in their native configurations, which access a class of antibodies that differ from those obtained by recombinant DNA or transgenic mouse methods.
The articles in this volume are definitive and comprehensive reviews written by experts who have sought to define the principles of viral neutralization by human antibodies. They explore and anticipate the obstacles and opportunities that will be encountered as the power of human antibodies is harnessed to address the vast, un-met need for effective anti-viral therapeutics.


From the reviews:

"The articles in this book focus on the use of antibodies for the treatment of viral infectious diseases. ... The book is written for anyone who has an interest in vaccine development. An advanced graduate student would have no trouble understanding this information. ... For anyone interested in antibody therapeutics for viral diseases, this would be a useful book. The chapters are well written and detailed. The bibliography for each chapter is extensive. It would be a welcome addition to a department or school library." (Marion C. Cohen, Doody's Review Service, July, 2008)


Redaktor Scott K. Dessain

Szczegóły produktu


GTIN 9783540721444

Data premiery rynkowej 12.10.2007

Język Angielski

Liczba stron 190

Product type Książka

Wielkość 235 x 155 x 155  mm

Ciężar produktu 477 g

746,79 zł
Na naszej stronie wykorzystujemy pliki cookies, aby strona była jeszcze bardziej funkcjonalna i przyjazna użytkownikowi. Prosimy kliknąć „Akceptuj cookies”! Więcej informacji znajdziesz w Polityce prywatności.